Key result
Treatment of apolipoprotein E-null mice with hexarelin resulted in a significant reduction in atherosclerotic lesions through a PPARgamma-dependent pathway.
Population
THP-1 macrophages and apolipoprotein E-null mice maintained on a lipid-rich diet
Design
Preclinical
Authors
Loading...
Does not support clinical use; hypothesis-generating for PPARgamma agonism in human atherosclerosis.
Hexarelin reduces atherosclerotic lesions in ApoE-null mice by upregulating sterol transporters and cholesterol efflux via a PPARgamma-dependent pathway.
Avallone et al. (2006) studied Atherosclerosis. Hexarelin was evaluated on Atherosclerotic lesions. Treatment of apolipoprotein E-null mice with hexarelin resulted in a significant reduction in atherosclerotic lesions through a PPARgamma-dependent pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: